Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS.

Background and Objectives  Mirasol® pathogen reduction technology (PRT) for platelet concentrates uses riboflavin and ultraviolet light. Previously, we described increased metabolism and activation for PRT platelets stored in 100% plasma. To improve platelet quality, we resuspended platelets in a mixture of plasma and platelet additive solution (PAS). Materials and Methods  Single-donor platelets were resuspended in plasma and split into an untreated control and a PRT-treated single product. One hundred and fifty millilitre PAS (SSP+) was added to both. Over 7 days, we assayed pH, glucose consumption-, lactate production rate and CD62p with and without TRAP. Results  On day 5, PRT units showed a significantly lower pH (7·087 ± 0·105 vs. 7·288 ± 0·200) accompanied by a higher lactate production (0·104 ± 0014 vs. 0·063 ± 0·017 mmol/1012/h) and glucose consumption rate (0·039 ± 0005 vs. 0·028 ± 0·009 mmol/1012 platelets/h). CD62p expression was higher in treated units (44·5 ± 13·0 vs. 16·5 ± 7·6%). Conclusion  In comparison to PRT platelets resuspended in 100% plasma, a mixture of plasma and PAS improves pH and platelet metabolism but not platelet activation. Prolonged shelf-life for up to 7 days may be possible.